FDA — authorised 2 January 2003
- Application: BLA103764
- Marketing authorisation holder: NOVARTIS
- Indication: Supplement
- Status: approved
🇺🇸 Chrft5 in United States
FDA authorised Chrft5 on 2 January 2003
Marketing authorisation
Chrft5 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Chrft5 approved in United States?
Yes. FDA authorised it on 2 January 2003.
Who is the marketing authorisation holder for Chrft5 in United States?
NOVARTIS holds the US marketing authorisation.